Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 3, 2011, Pages

  Prescott, David ^a   McKay, Derek M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Inflammatory bowel disease; Lipid mediators; Resolution

Indexed keywords

ASPIRIN TRIGGERED LIPOXIN; CHEMOKINE RECEPTOR CCR7; FORMYLPEPTIDE RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOXIN A; LIPOXIN RECEPTOR; MANNOSE; PHOSPHATIDYLINOSITOL 3 KINASE; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE; MACROPHAGE; OPSONIZATION; PATHOGEN LOAD; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; UPREGULATION;

ASPIRIN; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; CROHN DISEASE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; LIPOXINS; MACROPHAGES; PHAGOCYTOSIS; RECEPTORS, CCR7; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; UP-REGULATION;

EID: 80052284106     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00042.2011     Document Type: Article

References (59)

1. Bannenberg G, Moussignac RL, Gronert K, Devchand PR, Schmidt BA, Guilford WJ, Bauman JG, Subramanyam B, Perez HD, Parkinson JF, Serhan CN. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143: 43-52, 2004.
2. Bannenberg GL, Aliberti J, Hong S, Sher A, Serhan C. Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J Exp Med 199: 515-523, 2004.
3. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962, 2008.
4. Bernstein HG, Keilhoff G, Reiser M, Freese S, Wetzker R. Tissue distribution and subcellular localization of a G-protein activated phosphoinositide 3-kinase. An immunohistochemical study. Cell Mol Biol 44: 973-983, 1998.
5. Bonnans C, Gras D, Chavis C, Mainprice B, Vachier I, Godard P, Chanez P. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed Pharmacother 61: 261-267, 2007.
6. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 58: 463-487, 2006.
7. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92: 9475-9479, 1995.
8. Decker Y, McBean G, Godson C. Lipoxin A4 inhibits IL-1_-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am J Physiol Cell Physiol 296: C1420-C1427, 2009.
9. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Acquisto F, Buckingham JC, Perretti M, Flower RJ. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 184: 2611-2619, 2010.
10. Fadok VA, Warner ML, Bratton DL, Henson PM. CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (αvβ3). J Immunol 161: 6250-6257, 1998.
11. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, Suramanyam B, Guilford WJ, Parkinson JF. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 101: 15736-15741, 2004.
12. Fleit HB, Kobasiuk CD. The human monocyte-like cell line THP-1 expresses FcγRI and FcγRII. J Leukoc Biol 49: 556-565, 1991.
13. Fratti RA, Backer JM, Gruenberg J, Corvera S, Deretic V. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 154: 631-644, 2001.
14. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, Williams IR, Neish AS, Madara JL. Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 168: 5260-5267, 2002.
15. Ghia JE, Galeazzi F, Ford DC, Hogaboam CM, Vallance BA, Collins S. Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol 294: G770-G777, 2008.
16. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663-1667, 2000.
17. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964, 2005.
18. Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 10: 387-395, 1995.
19. Gronert K, Gewirtz A, Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor-α- induced IL-8 release. J Exp Med 187: 1285-1294, 1998.
20. Hashimoto A, Hayashi I, Murakami Y, Sato Y, Kitasato H, Matsushita R, Iizuka N, Urabe K, Itoman M, Hirohata S, Endo H. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol 34: 2144-2153, 2007.
21. Heinsbroek SE, Gordon S. The role of macrophages in inflammatory bowel diseases. Expert Rev Mol Med 11: e14, 2009.
22. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81: 1607-1613, 1993.
23. Hunter MM, Wang A, Parhar KS, Johnston MJ, Van Rooijen N, Beck PL, McKay DM. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138: 1395-1405, 2010.
24. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NFB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 99: 13266-13271, 2002.
25. Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-_ axis. J Clin Invest 118: 2269-2280, 2008.
26. Kamada N, Hisamatsu T, Okamoto S, Sato T, Matsuoka K, Arai K, Nakai T, Hasegawa A, Inoue N, Watanabe N, Akagawa KS, Hibi T. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol 175: 6900-6908, 2005.
27. Knight J, Lloyd-Evans P, Rowley AF, Barrow SE. Effect of lipoxins and other eicosanoids on phagocytosis and intracellular calcium mobilisation in rainbow trout (Oncorhynchus mykiss) leukocytes. J Leukoc Biol 54: 518-522, 1993.
28. Koch S, Kucharzik T, Heidemann J, Nusrat A, Luegering A. Investigating the role of proinflammatory CD16 monocytes in the pathogenesis of inflammatory bowel disease. Clin Exp Immunol 161: 332-341, 2010.
29. Kronke G, Katzenbeisser J, Uderhardt S, Zaiss MM, Scholtysek C, Schabbauer G, Zarbock A, Koenders MI, Axmann R, Zwerina J, Baenckler HW, van den Berg W, Voll RE, Kuhn H, Joosten LA, Schett G. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 183: 3383-3389, 2009.
30. Kure I, Nishiumi S, Nishitani Y, Tanoue T, Ishida T, Mizuno M, Fujita T, Kutsumi H, Arita M, Azuma T, Yoshida M. Lipoxin A4 reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappa-B activation. J Pharmacol Exp Ther 332: 541-548, 2010.
31. Le Y, Gong W, Li B, Dunlop NM, Shen W, Su SB, Ye RD, Wang JM. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 163: 6777-6784, 1999.
32. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612-619, 2001.
33. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med 8: 1018-1023, 2002.
34. Loddenkemper C. Diagnostic standards in the pathology of inflammatory bowel disease. Dig Dis 27: 576-583, 2009.
35. Maderna P, Cottell DC, Berlasconi G, Petasis NA, Brady HR, Godson C. Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am J Pathol 160: 2275-2283, 2002.
36. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 genedeficient mice. Gastroenterology 118: 1094-1105, 2000.
37. Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 79: 84-92, 2006.
38. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451-483, 2009.
39. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14: 1929-1934, 2004.
40. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 17: 501-519, 2006.
41. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, Brady HR, Godson C. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13: 2497-2507, 2002.
42. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 73: 209-212, 2003.
43. Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156: 2264-2272, 1996.
44. Prieto P, Cuenca J, Traves PG, Fernandez-Velasco M, Martin-Sanz P, Bosca L. Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways. Cell Death Differ 17: 1179-1188, 2010.
45. Qualls JE, Kaplan AM, van Rooijen N, Cohen DA. Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol 80: 802-815, 2006.
46. Reville K, Crean JK, Vivers S, Dransfield I, Godson C. Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 176: 1878-1888, 2006.
47. Ruckle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 5: 903-918, 2006.
48. Salzman NH, Bevins CL. Negative interactions with the microbiota: IBD. Adv Exp Med Biol 635: 67-78, 2008.
49. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3: 1101-1108, 2008.
50. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874, 2007.
51. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73: 141-162, 2005.
52. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325-332, 2007.
53. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75, 2005.
54. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nurnberg B, Gierschik P, Seedort K, Husan JJ, Waterfield MD, Wetzker R. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269: 690-693, 1995.
55. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 23: 901-944, 2005.
56. Vance RE, Hong S, Gronert K, Serhan CN, Mekalanos JJ. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 101: 2135-2139, 2004.
57. Wu SH, Liao PY, Dong L, Chen ZQ. Signal pathway involved in inhibition by lipoxin A4 of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm Res 57: 430-437, 2008.
58. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434, 2007.
59. Ye XH, Wu Y, Guo PP, Wang J, Yuan SY, Shang Y, Yao SL. Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res 1323: 174-183, 2010.